These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27156742)

  • 1. Monitoring serum etanercept levels in juvenile idiopathic arthritis: a pilot study.
    Alcobendas R; Rodríguez-Vidal A; Pascual-Salcedo D; Murias S; Remesal A; Diego C; Merino R
    Clin Exp Rheumatol; 2016; 34(5):955-956. PubMed ID: 27156742
    [No Abstract]   [Full Text] [Related]  

  • 2. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
    Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
    Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.
    Kahn R; Berthold E; Gullstrand B; Schmidt T; Kahn F; Geborek P; Saxne T; Bengtsson AA; Månsson B
    Acta Paediatr; 2016 Apr; 105(4):427-32. PubMed ID: 26707699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
    Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D
    Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia.
    Alexeeva EI; Namazova-Baranova LS; Bzarova TM; Valieva SI; Denisova RV; Sleptsova TV; Isaeva KB; Chomahidze AM; Taibulatov NI; Fetisova AN; Karaseva AV; Baranov AA
    Pediatr Rheumatol Online J; 2017 Jun; 15(1):51. PubMed ID: 28615036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
    Foeldvari I; Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
    Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
    Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response.
    Skrabl-Baumgartner A; Erwa W; Muntean W; Jahnel J
    Scand J Rheumatol; 2015; 44(5):359-62. PubMed ID: 25974288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.
    Shimizu M; Hamaguchi Y; Ishikawa S; Ueno K; Yachie A
    Mod Rheumatol; 2015; 25(6):972-3. PubMed ID: 25496406
    [No Abstract]   [Full Text] [Related]  

  • 10. Biologicals in Juvenile Idiopathic Arthritis.
    Saini I; Dawman L; Gupta N; Kabra SK
    Indian Pediatr; 2016 Mar; 53(3):260-1. PubMed ID: 27029697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Ann Rheum Dis; 2013 Apr; 72(4):627-8. PubMed ID: 23204515
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis.
    Geikowski T; Becker I; Horneff G;
    Rheumatology (Oxford); 2014 Jul; 53(7):1245-9. PubMed ID: 24599916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of etanercept.
    Llinares-Tello F; Rosas-Gómez de Salazar J; Senabre-Gallego JM; Santos-Soler G; Santos-Ramírez C; Salas-Heredia E; Molina-García J;
    Clin Chem Lab Med; 2015 Sep; 53(10):e279-82. PubMed ID: 26021413
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current therapy of polyarticular forms of juvenile idiopathic arthritis].
    Hospach A; Rühlmann JM; Weller-Heinemann F
    Z Rheumatol; 2016 Apr; 75(3):284-91. PubMed ID: 27001055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis.
    Lepore L; Marchetti F; Facchini S; Leone V; Ventura A
    Clin Exp Rheumatol; 2003; 21(2):276-7. PubMed ID: 12747299
    [No Abstract]   [Full Text] [Related]  

  • 17. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.
    van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM
    Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.
    Holzinger D; Frosch M; Kastrup A; Prince FH; Otten MH; Van Suijlekom-Smit LW; ten Cate R; Hoppenreijs EP; Hansmann S; Moncrieffe H; Ursu S; Wedderburn LR; Roth J; Foell D; Wittkowski H
    Ann Rheum Dis; 2012 Jun; 71(6):974-80. PubMed ID: 22267331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept treatment for children with refractory juvenile idiopathic arthritis.
    Kuo HC; Yu HR; Wu CC; Chang LS; Yang KD
    J Microbiol Immunol Infect; 2011 Feb; 44(1):52-6. PubMed ID: 21531353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept and urticaria in patients with juvenile idiopathic arthritis.
    Skyttä E; Pohjankoski H; Savolainen A
    Clin Exp Rheumatol; 2000; 18(4):533-4. PubMed ID: 10949736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.